Application of repeated respiratory mask with carbon dioxide concentration monitoring function in hyperventilation syndrome

Objective To investigate the application of repeated respiratory mask with carbon dioxide concentration monitoring function in hyperventilation syndrome(HVS),in order to provide more reference for clinical rescue of HVS patients. Methods From December 2017 to December 2018, 60 HVS patients admitted to the emergency department of our hospital were randomly divided into observation group(n=30) and control group(n=30) according to the random number table methods. The observation group received repeated respiratory mask with carbon dioxide concentration monitoring function, while the control group received plastic bag instead of nasal/mouth mask. Then the symptom remission time, Nijmegen score, blood gas analysis index, treatment effect, satisfaction and nursing cost were observed and compared between the two groups. Results The symptom remission time of the observation group was significantly shorter than that of the control group[(0.52±0.36) h vs.(1.13±0.42) h, t=6.040, P<0.001]. The Nijmegen score of the observation group was significantly lower than that of the control group[(7.23±3.56) scores vs(11.57±3.84) scores, t=4.540, P<0.001]. Blood pH was decreased in both groups after treatment, and was more obvious in the observation. PCO₂ level was increased in both groups after treatment, and was more significant in the observation group than in the control group. The clinical efficacy of the observation group was higher than that of the control group(93.33% vs. 66.67%, χ²=6.667, P=0.010). The satisfaction rate of the observation group was significantly higher than that of the control group(96.67% vs. 60.00%, χ²=11.882, P=0.001). The nursing cost of the observation group was significantly lower than that of the control group[(551.23±24.26) yuan vs.(875.42±26.87) yuan, t=49.050, P<0.001]. Conclusion The repeated respiratory mask with carbon dioxide concentration monitoring function is safe, effective and cheap for HVS patients, which can significantly shorten the time of disease onset and reduce the cost, so it is worthy of clinical promotion.